128 related articles for article (PubMed ID: 20934769)
1. Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Rhee SY; Kim YS; Chon S; Oh S; Woo JT; Kim SW; Kim JW
Diabetes Res Clin Pract; 2011 Jan; 91(1):e11-4. PubMed ID: 20934769
[TBL] [Abstract][Full Text] [Related]
2. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
[TBL] [Abstract][Full Text] [Related]
3. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for primary prevention of cardiovascular events in diabetes: still an open question.
Nicolucci A
JAMA; 2008 Nov; 300(18):2180-1. PubMed ID: 18997199
[No Abstract] [Full Text] [Related]
5. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
Angiolillo DJ; Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Sumner S; Desai B; Charlton RK; Box LC; Zenni M; Guzman LA; Bass TA
Thromb Haemost; 2011 Aug; 106(2):253-62. PubMed ID: 21614414
[TBL] [Abstract][Full Text] [Related]
6. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
7. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
[TBL] [Abstract][Full Text] [Related]
8. Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
Wienbergen H; Senges J; Gitt AK
Diabetes Care; 2008 Feb; 31 Suppl 2():S222-5. PubMed ID: 18227489
[No Abstract] [Full Text] [Related]
9. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Chen KY; Rha SW; Li YJ; Poddar KL; Jin Z; Minami Y; Wang L; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
Circulation; 2009 Jun; 119(25):3207-14. PubMed ID: 19528339
[TBL] [Abstract][Full Text] [Related]
10. Aspirin for primary prevention of cardiovascular events in people with diabetes.
Pignone M; Alberts MJ; Colwell JA; Cushman M; Inzucchi SE; Mukherjee D; Rosenson RS; Williams CD; Wilson PW; Kirkman MS; ; ;
J Am Coll Cardiol; 2010 Jun; 55(25):2878-86. PubMed ID: 20579547
[No Abstract] [Full Text] [Related]
11. Aspirin therapy in diabetes mellitus.
Colwell JA
Diabetologia; 1997 Jul; 40(7):867. PubMed ID: 9243111
[No Abstract] [Full Text] [Related]
12. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
[TBL] [Abstract][Full Text] [Related]
13. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.
Rao AK; Vaidyula VR; Bagga S; Jalagadugula G; Gaughan J; Wilhite DB; Comerota AJ
Thromb Haemost; 2006 Dec; 96(6):738-43. PubMed ID: 17139367
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus.
Bulatova NR; Yousef AM; AbuRuz SM
Thromb Res; 2007; 121(1):43-50. PubMed ID: 17462716
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of aspirin resistance in patients with type 2 diabetes.
Fateh-Moghadam S; Plöckinger U; Cabeza N; Htun P; Reuter T; Ersel S; Gawaz M; Dietz R; Bocksch W
Acta Diabetol; 2005 Jun; 42(2):99-103. PubMed ID: 15944844
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease].
Soejima H; Ogawa H
Nihon Rinsho; 2010 May; 68(5):882-6. PubMed ID: 20446587
[TBL] [Abstract][Full Text] [Related]
19. [Arterial risk in type 2 diabetes: from mega-trials to prescription].
Bonnet F; Moulin P
Rev Prat; 2003 May; 53(10):1095-101. PubMed ID: 12846030
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin.
Krayenbuehl PA; Wiesli P; Schmid M; Schmid C; Ehses JA; Hersberger M; Vetter W; Schulthess G
Exp Clin Endocrinol Diabetes; 2007 May; 115(5):322-6. PubMed ID: 17516296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
